BetterLife Pharma Inc. (BETRF)
USD 0.07
(0.0%)
USD 0.07
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -2.88 Million CAD | 67.96% |
| 2023 | -9.05 Million CAD | 25.5% |
| 2022 | -12.15 Million CAD | 66.55% |
| 2021 | -36.35 Million CAD | -81.16% |
| 2020 | -20.06 Million CAD | -119.39% |
| 2019 | -9.14 Million CAD | -6017.78% |
| 2018 | -149.5 Thousand CAD | 98.18% |
| 2017 | -8.22 Million CAD | 31.39% |
| 2016 | -11.99 Million CAD | -1096.03% |
| 2015 | -1 Million CAD | -32.98% |
| 2014 | -753.87 Thousand CAD | -320.8% |
| 2013 | 341.42 Thousand CAD | -75.92% |
| 2012 | 1.41 Million CAD | 146.9% |
| 2011 | -3.02 Million CAD | -2416.41% |
| 2010 | -120.13 Thousand CAD | 81.62% |
| 2009 | -653.76 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 FY | -2.88 Million CAD | 68.11% |
| 2024 Q3 | -195.45 Thousand CAD | 80.82% |
| 2024 Q1 | -1.08 Million CAD | -331.77% |
| 2024 Q4 | -1.3 Million CAD | -566.4% |
| 2024 Q2 | -1.01 Million CAD | -5.77% |
| 2023 Q2 | -865.66 Thousand CAD | 70.28% |
| 2023 Q1 | -2.91 Million CAD | 26.05% |
| 2023 Q4 | -75.62 Thousand CAD | 98.51% |
| 2023 Q3 | -5.07 Million CAD | -486.23% |
| 2023 FY | -9.05 Million CAD | 25.5% |
| 2022 Q3 | -2.2 Million CAD | 38.15% |
| 2022 FY | -12.15 Million CAD | 66.55% |
| 2022 Q2 | -3.56 Million CAD | -46.08% |
| 2022 Q1 | -2.44 Million CAD | 91.12% |
| 2022 Q4 | -3.93 Million CAD | -78.39% |
| 2021 Q3 | -7.34 Million CAD | -370.71% |
| 2021 FY | -36.35 Million CAD | -81.16% |
| 2021 Q1 | 378.96 Thousand CAD | 103.55% |
| 2021 Q2 | -1.56 Million CAD | -511.99% |
| 2021 Q4 | -27.5 Million CAD | -274.27% |
| 2020 Q3 | -2.59 Million CAD | 40.9% |
| 2020 Q2 | -4.38 Million CAD | -134.12% |
| 2020 Q1 | -1.87 Million CAD | -157.38% |
| 2020 FY | -20.06 Million CAD | -119.39% |
| 2020 Q4 | -10.67 Million CAD | -311.47% |
| 2019 Q4 | -728.16 Thousand CAD | 83.57% |
| 2019 Q2 | -1.84 Million CAD | 11.67% |
| 2019 Q3 | -4.43 Million CAD | -140.45% |
| 2019 Q1 | -2.08 Million CAD | -405.24% |
| 2019 FY | -9.14 Million CAD | -6017.78% |
| 2018 Q2 | -6924.72 CAD | 98.41% |
| 2018 FY | -149.5 Thousand CAD | 98.18% |
| 2018 Q4 | -412.96 Thousand CAD | -160.65% |
| 2018 Q3 | 680.87 Thousand CAD | 9932.5% |
| 2018 Q1 | -436.4 Thousand CAD | 51.19% |
| 2017 FY | -8.22 Million CAD | 31.39% |
| 2017 Q1 | -4.18 Million CAD | 45.02% |
| 2017 Q4 | -894.04 Thousand CAD | 30.21% |
| 2017 Q2 | -1.54 Million CAD | 63.17% |
| 2017 Q3 | -1.28 Million CAD | 16.84% |
| 2016 Q4 | -7.6 Million CAD | -73621.67% |
| 2016 FY | -11.99 Million CAD | -1096.03% |
| 2016 Q1 | -1.45 Million CAD | -63.94% |
| 2016 Q2 | -2.93 Million CAD | -101.47% |
| 2016 Q3 | -10.32 Thousand CAD | 99.65% |
| 2015 Q3 | -167.72 Thousand CAD | -360.01% |
| 2015 FY | -1 Million CAD | -32.98% |
| 2015 Q1 | 90.76 Thousand CAD | 264.65% |
| 2015 Q2 | -36.46 Thousand CAD | -140.17% |
| 2015 Q4 | -889.11 Thousand CAD | -430.12% |
| 2014 Q2 | -48.2 Thousand CAD | 1.66% |
| 2014 Q4 | -55.12 Thousand CAD | 90.84% |
| 2014 Q3 | -601.53 Thousand CAD | -1147.94% |
| 2014 Q1 | -49.01 Thousand CAD | 28.87% |
| 2014 FY | -753.87 Thousand CAD | -320.8% |
| 2013 Q2 | -122.91 Thousand CAD | -120.7% |
| 2013 FY | 341.42 Thousand CAD | -75.92% |
| 2013 Q1 | 593.9 Thousand CAD | 161.84% |
| 2013 Q3 | -60.65 Thousand CAD | 50.66% |
| 2013 Q4 | -68.91 Thousand CAD | -13.62% |
| 2012 Q3 | 129.57 Thousand CAD | -3.03% |
| 2012 Q2 | 133.62 Thousand CAD | -93.68% |
| 2012 FY | 1.41 Million CAD | 146.9% |
| 2012 Q4 | -960.35 Thousand CAD | -841.17% |
| 2012 Q1 | 2.11 Million CAD | 172.1% |
| 2011 Q2 | -42.52 Thousand CAD | -57.19% |
| 2011 Q4 | -2.93 Million CAD | -14431.36% |
| 2011 Q3 | -20.18 Thousand CAD | 52.53% |
| 2011 FY | -3.02 Million CAD | -2416.41% |
| 2011 Q1 | -27.05 Thousand CAD | -56.75% |
| 2010 Q4 | -17.25 Thousand CAD | -22.26% |
| 2010 Q2 | -75.96 Thousand CAD | -493.3% |
| 2010 FY | -120.13 Thousand CAD | 81.62% |
| 2010 Q3 | -14.11 Thousand CAD | 81.42% |
| 2010 Q1 | -12.8 Thousand CAD | 0.0% |
| 2009 FY | -653.76 Thousand CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 96.146% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 56.068% |
| SQZ Biotechnologies Company | -79.46 Million USD | 96.364% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 105.453% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 104.436% |
| Mesoblast Limited | -87.95 Million USD | 96.715% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -58.692% |
| Genus plc | 7.9 Million USD | 136.57% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 73.475% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 22.133% |
| Marizyme, Inc. | -65.34 Million USD | 95.579% |
| ContraFect Corporation | -65.15 Million USD | 95.566% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 67.333% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 40.872% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -67.242% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 0.116% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 64.155% |
| MultiCell Technologies, Inc. | -380.07 USD | -760031.555% |
| Accustem Sciences Inc. | -3.74 Million USD | 22.886% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 94.411% |
| EV Biologics, Inc. | -1.26 Million USD | -127.997% |
| Q BioMed Inc. | -2.05 Million USD | -40.785% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 22.608% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -356.831% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -21.344% |
| Biomind Labs Inc. | -1.21 Million USD | -137.914% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -10.54 Million USD | 72.611% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 63.444% |
| Skye Bioscience, Inc. | -37.64 Million USD | 92.326% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -33.147% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -19191.079% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 58.627% |
| IMV Inc. | -36.48 Million USD | 92.082% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 81.797% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 50.337% |
| GB Sciences, Inc. | -1.36 Million USD | -112.167% |
| Alpha Cognition Inc. | -13.77 Million USD | 79.023% |
| HST Global, Inc. | -146.21 Thousand USD | -1875.947% |
| CSL Limited | 2.64 Billion USD | 100.109% |
| Halberd Corporation | -79.67 Thousand USD | -3525.975% |
| Enzolytics Inc. | -2.17 Million USD | -32.717% |
| Resverlogix Corp. | -3.61 Million USD | 19.971% |
| Affymax, Inc. | -14.42 Million USD | 79.971% |
| SYBLEU INC | -180.3 Thousand USD | -1502.312% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 8.905% |
| argenx SE | -295.05 Million USD | 99.021% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 95.385% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 3047.992% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 27.283% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 4.531% |
| AVAX Technologies, Inc. | -6.41 Million USD | 54.955% |
| Zenith Capital Corp. | -10.59 Million USD | 72.735% |
| Genscript Biotech Corporation | -95.47 Million USD | 96.974% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -12330.221% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 30.317% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -4679.952% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 95.163% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 6.859% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.05 Million USD | -173.568% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -48.213% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 24.351% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -44.083% |
| BioStem Technologies, Inc. | -8.48 Million USD | 65.943% |
| ONE Bio Corp. | 8.67 Million USD | 133.297% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -554.562% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -116.337% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -64.639% |
| Agentix Corp. | -1.37 Million USD | -110.232% |
| LadRx Corporation | 400.44 Thousand USD | 821.459% |
| Cell Source, Inc. | -5.32 Million USD | 45.707% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -595.35% |
| Regen BioPharma, Inc. | 1.02 Million USD | 382.268% |
| Regen BioPharma, Inc. | 1.02 Million USD | 382.268% |
| NovAccess Global Inc. | -4.76 Million USD | 39.423% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 141.721% |
| Itoco Inc. | -1.86 Million USD | -54.577% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 34.969% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -73.1% |
| Kadimastem Ltd | -3.3 Million USD | 12.649% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -956.697% |
| CytoDyn Inc. | -49.84 Million USD | 94.204% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -3555.476% |
| Mobile Lads Corp. | -2.26 Million USD | -27.647% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -1166.414% |
| Qrons Inc. | -789.34 Thousand USD | -266.003% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -206.845% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -38.385% |
| Rebus Holdings, Inc. | -1.02 Million USD | -183.238% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -79.138% |
| International Stem Cell Corporation | -131 Thousand USD | -2105.368% |
| Bioxytran, Inc. | -4.28 Million USD | 32.499% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -5223.246% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -14.18% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 93.99% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -36.662% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -269.968% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 8.806% |
| Neutra Corp. | -233.46 Thousand USD | -1137.458% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 85.762% |
| PureTech Health plc | -65.69 Million USD | 95.602% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 86.415% |
| IXICO plc | -1.17 Million USD | -145.249% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 70.897% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 94.943% |
| CSL Limited | 2.64 Billion USD | 100.109% |
| Cellectis S.A. | -103.17 Million USD | 97.2% |